Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice

Journal of Toxicological Sciences

Volumn 32, Issue 4, 2007, Pages 367-375

  Urano, Koji ^a   Suzuki, Shuzo ^a   Machida, Kazuhiko ^a   Eguchi, Natsuko ^a   Sawa, Nobuko ^a   Kikuchi, Koji ^b   Hattori, Yuji ^a   Usui, Toshimi ^a  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^b JAC Inc ^*  (Japan)

Author keywords

Carcinogenicity; Percutaneous administration; rasH2 mice; Short term carcinogenicity test; Transgenic mice

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARCINOGENICITY; CELL HYPERPLASIA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; KERATOACANTHOMA; MALE; MOUSE; NONHUMAN; SKIN PAPILLOMA;

MUS; MUS MUSCULUS;

EID: 35649015359     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.367     Document Type: Article

References (18)

1. Blanchard, K.T., Ball, D.J., Holden, H.E., Furst, S.M., Stoltz, J.H. and Stoll, R.E. (1998): Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-o-tetradecanoylphorbol 13-acetate (TPA) and Benzene. Toxicol. Pathol., 26, 541-547.
2. Cannon, R.E., Spalding, J. W., Trempus, C.S., Szczesniak, C.J., Virgil, K.M., Humble, M.C. and Tennant, R.W. (1997): Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol. Carcinog., 20, 108-114.
3. Eastin, W.C., Mennear, J.H., Tennant, R.W., Stoll, R.E. , Branstetter, D.G., Bucher, J. R., McCullough, B., Binder, R.L., Spalding, J.W. and Mahler, J.F. (2001): Tg.AC genetically altered mouse: Assay working group overview of available data. Toxicol. Pathol., 29 (Suppl.), 60-80.
4. Hansen, L.A., Spalding, J.W., French, J.E. and Tennant, R.W. (1995): A transgenic mouse model (Tg.AC) for skin carcinogenesis: Inducible transgene expression as a second critical event. Prog. Clin. Biol. Res., 391, 223-235.
5. Honchel, R., Rosenzweig, B.A., Thompson, K.L., Blanchard, K.T., Furst, S.M., Stoll, R.E. and Sistare, F.D. (2001): Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Molecular Carcinogenesis, 30, 99-110.
6. Leder, A., Kuo, A., Cardiff, R.D., Sinn, E. and Leder, P. (1990): v-Ha-ras-transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA, 87, 9178-9182.
7. MacDonald, J., French, J.E., Gerson, R.J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F.D., Storer, R. and van der Laan, J.W. (2004): The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. Toxicol. Sci., 77, 188-194.
8. National Toxicology Program (1989): Toxicology and carcinogenesis studies of 4-vinyl-1- cyclohexene diepoxide (CAS No. 106-87-6) in F344/N rats and B6C3F1 mice, NTP TR 362, NIH Publication No. 90-2817.
9. Ohkawa, Y., Iwata, K. and Inui, N. (1988): Screening for skin-tumor promoters. Biomed. Pharmacother., 42, 447-450.
10. Radman, M. and Kinsella, A.R. (1980): Chromosomal events in carcinogenic initiation and promotion: Implications for carcinogenicity testing and cancer prevention strategies. IARC Sci. Publ., 27, 75-90.
11. Spalding, J.W., French, J.E., Tice, R.R., Furedi-Machacek, M., Haseman, J.K. and Tennant, R.W. (1999): Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol. Sci., 49. 241-254.
12. Stoll, R.E., Furst, S.M., Stoltz, J.H., Lilly, P.D. and Mennear, J.H. (2001): Dermal carcinogenicity in transgenic mice: Effect of vehicle on responsiveness of hemizygous Tg.AC mice to phorbol 12-myristate 13-acetate (TPA). Toxicol. Pathol., 29, 535-540.
13. Takaoka, M., Sehata, S., Maejima, T., Imai, T., Torii, M., Satoh, H., Toyosawa, K., Tanakamaru, Z., Adachi, T., Hisada, S., Ueda, M., Ogasawara, H., Matsumoto, M., Kobayashi, K., Mutai, M. and Usui, T. (2003): Interlaboratory camparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol. Pathol., 31, 191-199.
14. Tamaoki, N. (2001): The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol., 29 (Suppl.), 81-89.
15. Thompson, K.L., Rosenzweig, B.A. and Sistare, F.D. (1998): An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol., 26, 548-555.
16. Usui, T., Mutai, M., Hisada, S., Takaoka, M., Soper, K.E., McCullough, B. and Alden, C. (2001): CB6F1-rasH2 mouse: overview of available data. Toxicol. Pathol., 29 (Suppl.), 90-108.
17. Weaver, J.L., Contrera, J.F., Rosenzweig, B.A., Thompson, K.L., Faustine, P.J., Strong, J.M., Ellison, C.D., Anderson, L.W., Prasanna, H.R., Long-Bradley, P.E., Lin, K.K., Zhang, J. and Sistare, F.D. (1998): An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol., 26, 532-540.
18. Yamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., Mitsumori, K., Kurokawa, Y., Hayashi, Y. and Nomura, T. (1998): Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for carcinogenicity testing. Environment. Health Perspect., 106 (Supple. 1), 57-69.